Procter & Gamble

8 billion, and the price speaks volumes. 97, about 15% below its 52-week high. Investors scrutinizing this transaction are looking for an answer: Is P&G buying growth it can't generate on its own, or is it finally acting on the health-and-beauty focus management has been describing for months? The stock rose about 1% on the announcement, then stagnated, pressured three days later by an Argus downgrade to "Hold". This mixed reaction illustrates the current tension. P&G is making a real move towards the fastest-growing segment of its portfolio, yet the stock is valued as if nothing has changed.

The acquisition, the downgrade, and a new fourth quarter give investors enough to judge whether the repositioning is working. Thorne is a science-based supplement brand, created in 1984, and its appeal is demographic: about 60% of its revenue comes from consumers under 40, with sales rapidly shifting towards direct-to-consumer channels and annual revenue exceeding $500 million in 2025. 6 times in about three years. This high price explains the market's hesitation, and Paul Gama, head of healthcare at P&G, presented the acquisition as a purchase in premium wellness, not a bargain.

It is expected to be finalized later this year, subject to regulatory approvals. CEO Shailesh Jejurikar argued that the next phase of growth will come from higher-growth segments and "bigger more" innovation, telling analysts that the United States and Europe still offer "growth opportunities of $5 billion to $10 billion over the next 3 to 5 years." Thorne fits this thesis. 5 billion in fiscal year 2026. This segment sits alongside a Beauty and Skin Care business that grew at an average pace over the year and an international branch now inflecting, with China gaining market share "for the first time in 15 quarters" and SK-II up 8% there, excluding duty-free sales.

Adding a wellness brand for Generation Z and millennials to this mix is realizing portfolio rebalancing, and P&G has played this card before: it has owned New Chapter vitamins since 2012 without altering the brand. See historical data and future estimates for P&G stock (It's free!) >>> Three days after the Thorne announcement, Argus analyst Chris Graja downgraded P&G from "Buy" to "Hold". His reasoning is the clearest version of the skeptical view: core operating margin has declined for three consecutive quarters, the stock has underperformed the S&P 500 and the consumer staples sector this year, and management provided fiscal year 2027 guidance with slowed growth of 1% to 3% for revenue and 0% to 3% for core EPS.

8 billion acquisition appears to bears as buying growth that organic activity is not producing. 52%, and organic sales returned to a flat level, with North America down 1% as shipments lagged consumption by 3 points due to Prime Day timing and retailer destocking. 41 estimate but was down 3% year-over-year, and management expects first-quarter fiscal year 2027 EPS to be down 5% or more before costs abate. 56 per share, which combines an impact of approximately $1 billion related to input costs (oil) with currency and interest rate pressures, and which is most felt in the first half.

S. business where the share of key brand-customer combinations growing or holding their shares increased from less than 10% to about 50% in fiscal year 2026. If this consumption recovery holds and costs compare to the prior year, margins will inflect, and flat quarters will give way to the growth recovery that analysts are already modeling. In terms of valuation, P&G trades at nearly 20 times forward earnings, a premium to Kimberly-Clark at about 15 times, and Reckitt Benckiser at nearly 14 times, but a discount to Colgate-Palmolive at about 23 times.

The premium over cheaper peers is defensible thanks to a historical operating margin close to 25%, category leadership in most of its ten segments, and the pricing power behind Tide and Pampers. See how P&G performs against its peers on TIKR (It's free!) >>> See analyst growth forecasts and price targets for P&G stock (It's free!) 9 years. This is a steady "compounder" return, not a re-rating, relying on earnings growth and P&G's 70-year streak of dividend increases rather than multiple expansion; the model assumes the P/E drifts slightly lower.

The Thorne acquisition will not be finalized for several months and is modest compared to P&G's $87 billion base, so it will not impact fiscal year 2027 figures. What it signals is where management places its convictions. The closest test will come with the first-quarter fiscal year 2027 results, expected in late October. Watch for two things: whether organic sales in North America turn positive as the gap between shipments and consumption narrows, and whether the core operating margin stops declining after three quarters of decline. S. with stabilizing margins will confirm that the repositioning is real.

Another flat quarter with still-declining margins would give bears a fourth data point, and the premium paid for Thorne would start to look like a distraction. Discover which stocks billionaire investors are buying to follow smart money with TIKR.